Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, January 27, 2023
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
Michael Ulz Upgraded (CABA) to Buy and Held Target at $16 on, Jan 27th, 2023
Michael Ulz of Morgan Stanley, Upgraded "Cabaletta Bio, Inc." (CABA) to Buy and Held Target at $16 on, Jan 27th, 2023.
Michael has made no other calls on CABA in the last 4 months.
There are 2 other peers that have a rating on CABA. Out of the 2 peers that are also analyzing CABA, 0 agree with Michael's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Michael
- Derek Archila of "Wells Fargo" Maintained at Buy with Increased Target to $14 on, Tuesday, January 3rd, 2023
- Geulah Livshits of "Chardan Capital" Maintained at Strong Buy with Decreased Target to $12 on, Friday, November 11th, 2022
